Ardelyx, Inc. Aktie News

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m.

WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.

WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the first patient has been dosed in ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of...

Ardelyx: Assessment Of Acquisition Rumors

Ardelyx has transformed into a commercial powerhouse with two FDA-approved, first-in-class drugs, IBSRELA and XPHOZAH, driving robust revenue growth. IBSRELA's rapid uptake and projected $410–$430 million 2026 revenue, alongside a patent extension to 2041, create a durable, generational asset and significant terminal value. XPHOZAH's $100M+ annual revenue confirms unmet need in hyperphosphatemi...

Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue 1

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data, including results from the first real-world study of XPHOZAH, at American Society of Nephrology's ...

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November ...